Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective is to assess the efficacy of IPH1101 associated with low dose of IL-2 as add-on therapy to imatinib in CML patients with residual molecular disease after at least 2 years of imatinib monotherapy.
Inclusion criteria
- Chronic myeloid leukemia